细胞染色体P-450 CYP2C19遗传多态性及其与克洛皮多格雷尔耐药性的关系
Usman Nawaz1, Mudassar Noor2, Akbar Waheed3
1Department of Pharmacology, CMH Kharian Medical College, Kharian, Pakistan.
JPMA. The Journal of the Pakistan Medical Association
|December 12, 2023
概括
CYP2C19*2遗传变异在缺血性心脏病患者中很常见,并且与较高的克洛皮多格雷尔耐药性有关. 这一发现强调了基因测试对于个性化抗血小板治疗的重要性.
科学领域:
- 药物基因组学 药物基因组学
- 心血管医学 心血管医学
- 临床遗传学 临床遗传学
背景情况:
- 缺血性心脏病 (IHD) 是全球主要的死亡原因.
- 克洛皮多格雷尔是一种广泛用于IHD患者的抗血小板药物.
- 遗传变异,如CYP2C19*2多态性,可以影响克洛皮多格雷尔的疗效.
研究的目的:
- 确定CYP2C19*2遗传多态性在患有缺血性心脏病的患者中的流行率.
- 调查不同CYP2C19*2基因型与克洛皮多格雷尔耐药性之间的关联.
主要方法:
- 一项涉及390名接受克洛皮多格雷尔治疗的缺血性心脏病患者的横截面研究.
- 使用聚合酶连锁反应-限制片段长度多态的CYP2C19*2基因型鉴定.
- 使用光传导聚合计进行血小板聚合分析.
主要成果:
- 在50.8%的患者中存在CYP2C19*2多态 (异合体40.8%,同合体9%).
- 与野生型 (*1/*1: 19.9%) 携带者相比,同卵性 (*2/*2: 48.6%) 和异卵性 (*1/*2: 25.8%) 携带者中的克洛皮多格勒耐药性显著更高 (p=0.001).
- 基因型组之间的平均血小板聚合有显著差异 (p=0.025).
结论:
- 克洛皮多格雷尔耐药性的患病率在CYP2C19*2等位基因的同位基因和异位基因携带者中都很高.
- 对CYP2C19*2的遗传查可能有助于优化IHD患者的克洛皮多格雷尔治疗.
- 基于药物遗传学的个性化抗血小板治疗策略是合理的.
相关概念视频
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
153
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
153
01:19Factors Affecting Drug Biotransformation: Biological
153
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
153
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
526
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
526
01:17Drug Metabolism: Phase I Reactions
3.3K
A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
3.3K
01:15Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response
64
Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
64
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K